Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,677	$ 15,364
Short-term investments	51,732	69,488
Accounts receivable, net	60,137	52,049
Inventory	42,110	54,573
Prepaid expenses and other current assets	6,118	13,961
Total current assets	188,774	205,435
Property and equipment, net	20,166	22,160
Right-of-use lease assets	5,438	7,645
Other assets	8,128	15,711
Total assets	222,506	250,951
Current liabilities:
Accounts payable	3,240	3,225
Accrued clinical and manufacturing liabilities	22,291	24,468
Accrued payroll and employee liabilities	9,224	13,416
Other accrued liabilities	41,855	38,552
Current lease liabilities	3,075	2,694
Total current liabilities	79,685	82,355
Non-current lease liabilities	2,800	5,499
Non-current notes payable, net	24,263
Non-current convertible notes payable, net	149,490	149,284
Other non-current liabilities	241	241
Total liabilities	256,479	237,379
Commitments and contingencies (see Note 6)
Stockholders’ equity:
Preferred stock, $0.01 par value: 2,500,000 shares authorized; no shares issued or outstanding at December 31, 2023 and 2022
Common stock, $0.01 par value: 225,000,000 shares authorized; 150,285,044 shares issued and outstanding at December 31, 2023 and 119,154,538 shares issued and outstanding at December 31, 2022	1,503	1,191
Additional paid-in capital	1,870,525	1,807,855
Accumulated other comprehensive income (loss)	13	(19)
Accumulated deficit	(1,906,014)	(1,795,455)
Total stockholders' (deficit) equity	(33,973)	13,572
Total liabilities and stockholders’ equity	$ 222,506	$ 250,951